Consequently, AML patients with very diverse pretreatment TRB repertoires as well as patients with “early-on-treatment” immunological response to AZA might benefit from the low-risk profile of AZA treatment compared to intensive chemotherapy while having an equivalent prognosis. This evidence concerns the gene THRB and acute myeloid leukemia.